CHRN vs NBIS: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

NBIS is the larger of the two ($35.20B market cap): the incumbent the market prices for continued execution (-39.86x forward earnings, beta 1.54). CHRN is the smaller challenger ($1.65B), priced similarly on forward earnings (65.03x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

CHRN vs NBIS: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricCHRNNBISWhat it tells you
Market cap$1.65B$35.20BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E65.03-39.86Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta1.101.54Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range30% of range29% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book11.013.68How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how CHRN and NBIS affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CHRN and NBIS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CHRN and NBIS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does ChronoScale Corporation (CHRN) do?

ChronoScale Corporation is a "neocloud," meaning it buys large clusters of NVIDIA GPUs, installs them in data centers, and rents that accelerated compute to companies running artificial intelligence workloads such as model training, inference, and high-performance computing. It began life as the cloud unit of Applied Digital, a data-center developer, and became a separate public company on May 5, 2026, when that cloud business was combined with the former shell of Ekso Bionics Holdings, which then renamed itself ChronoScale and kept the ticker CHRN on the Nasdaq Capital Market. The company is based in Dallas, Texas. In fiscal 2025 (the year ended May 2025) the cloud unit ran about 6,144 GPUs and generated roughly $84 million of revenue, up about 191% year over year, while posting a net loss of about $73 million as it invested to scale.

Full CHRN guide

What does Nebius Group (NBIS) do?

Nebius Group is an AI infrastructure company that builds and operates cloud platforms optimized for training and running artificial-intelligence models. It emerged from the international assets of the former Yandex business after Yandex's Russian operations were divested, and it relisted on Nasdaq as a standalone company headquartered in Amsterdam. Nebius's core business is an AI-focused cloud: it builds data centers packed with NVIDIA GPUs and rents that compute capacity to companies training large AI models, competing with the GPU-cloud and neocloud providers that have grown alongside the AI boom. The company designs its own server hardware and software stack to deliver high-performance, cost-efficient AI compute. Beyond the core cloud, Nebius holds several other technology businesses, including an autonomous-driving unit, an edtech platform, and a generative-AI data-labeling business, plus a stake in a data-center and other ventures. As a relatively young public company, Nebius is in a heavy-investment phase, spending aggressively on GPU capacity and data centers to capture AI-infrastructure demand, and is not yet consistently profitable. Over the trailing twelve months to June 2026, Nebius reported ~$1.36 billion of revenue, a gross margin near 74% and roughly break-even operating results, while capital spending pushed free cash flow to about -$9.6 billion. The balance sheet carried ~$8 billion of cash against ~$10.2 billion of debt as of mid-2026.

Full NBIS guide

CHRN vs NBIS: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • CHRN drivers: Riding AI compute demand; Independence and capital flexibility.
  • NBIS drivers: AI compute demand tailwind; Vertically integrated, cost-efficient stack.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The risks are substantial and stack together. For NBIS, nebius is an early-stage, capital-intensive business: building GPU data centers requires enormous upfront spending, and free cash flow was about -$9.6 billion over the trailing year to June 2026.

CHRN or NBIS: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CHRN if you believe its drivers more; NBIS if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CHRN and NBIS guides.

CHRN vs NBIS: the full fundamentals

CHRN. Figures are approximate and tied to the asOf date; verify live numbers before acting. At roughly 31 times trailing sales and with no earnings, ChronoScale is valued on the $1 billion run-rate revenue it says it has contracted for 2027 rather than on today's results. Analysts' estimates point the same way (about $132 million of revenue in the year to May 2027 and about $930 million the year after), which leaves the stock highly sensitive to any slip in deployments or financing.

NBIS. Nebius trades at ~32 times trailing sales, a valuation that leans on analysts' expectations of ~$3.3 billion in 2026 revenue and ~$12.3 billion in 2027 rather than on current profits. The shares are up ~91% year to date but have fallen ~23% in the past month as financing costs for neoclouds came into focus, and the next report, due November 10, 2026, is expected to show revenue near ~$905 million with a loss of ~$0.65 per share.

Headline figures (approximate, October 2026): CHRN shows revenue (fiscal q1 2027, to aug 2026) ~$41.5 million, up ~148% year over year, revenue (ttm) ~$72 million, net loss (fiscal q1 2027) ~-$26.4 million continuing ops; ~-$42.5 million total, adjusted ebitda (fiscal q1 2027) ~$5.9 million; NBIS shows revenue (ttm) ~$1.36 billion (to June 2026), revenue growth ~454% year over year in the June 2026 quarter (~$582 million), margins Gross ~74%; operating roughly break-even (~-0.2%), net income (ttm) ~$42 million, lifted by a large one-quarter gain in Q1 2026.

The bottom line: CHRN vs NBIS

CHRN and NBIS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CHRN and NBIS exposure against your real portfolio. It is not an investment adviser.

Wondering how CHRN or NBIS fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about ChronoScale Corporation

Ask Walnut's AI anything about CHRN and see how it fits what you own.

FAQ

What is the difference between CHRN and NBIS?

+

ChronoScale Corporation is a "neocloud," meaning it buys large clusters of NVIDIA GPUs, installs them in data centers, and rents that accelerated compute to companies running artificial intelligence workloads such as model training, inference, and high-performance computing. Nebius Group is an AI infrastructure company that builds and operates cloud platforms optimized for training and running artificial-intelligence models. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is CHRN or NBIS the better stock?

+

Neither is universally better. NBIS is the larger incumbent; CHRN is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, CHRN or NBIS?

+

On forward P/E (as of November 2026), CHRN trades at 65.03x and NBIS at -39.86x, so NBIS is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both CHRN and NBIS?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of CHRN vs NBIS?

+

CHRN: The risks are substantial and stack together. ChronoScale is deeply unprofitable: in the quarter to August 2026 cost of revenue (about $45.6 million) exceeded revenue (about $41.5 million), and the net loss from continuing operations was about $26.4 million. Building GPU capacity is extremely capital intensive, cash was only about $15 million at the end of August, and the October 2026 $500 million shelf filing points to future share or debt issuance that could dilute existing holders. The $1 billion run-rate target depends on deployment schedules, power and equipment availability, and access to capital, and the company itself says actual revenue may differ materially. Customer concentration is severe, so losing even one of a few large customers would badly hurt revenue. Applied Digital owns about 95% of the stock and collects a fee on gross revenue, leaving public holders with little control and a thin float that can swing sharply. GPUs depreciate fast and can be made obsolete by newer chips, while competition comes from far larger, better-funded rivals and from the hyperscalers themselves. As a newly public company created through a reverse merger with a former shell, it also carries limited standalone operating history and elevated volatility, with the stock down about 40% over the three months to mid-October 2026. NBIS: Nebius is an early-stage, capital-intensive business: building GPU data centers requires enormous upfront spending, and free cash flow was about -$9.6 billion over the trailing year to June 2026. Debt has grown to ~$10.2 billion, so rising borrowing costs or tighter credit for AI infrastructure (the worry that hit neocloud stocks in October 2026) could slow expansion or dilute shareholders. Reported earnings are lumpy: the March 2026 quarter showed a large profit (~$621 million) while the quarters on either side were losses, and analysts expect losses per share in the coming quarters, so the trailing P/E of ~137 says little about underlying profitability. It competes against hyperscalers (AWS, Azure, Google Cloud) with vast resources and against well-funded neoclouds like CoreWeave, plus NVIDIA's own cloud ambitions. The economics depend on keeping expensive GPUs highly utilized; any softening in AI demand, faster GPU depreciation, or price competition could pressure returns. Customer concentration, reliance on NVIDIA supply, and the complexity of its post-Yandex corporate history add uncertainty. The stock is volatile (its 52-week range runs from ~$74 to ~$300) and trades on growth expectations rather than current earnings.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell CHRN or NBIS; figures are approximate and dated (as of November 2026). Verify current data before investing.